Fisetin Clinical Trials: What Human Studies Are Actually Testing

Human fisetin research, explained

Human fisetin trials are underway, but they have not yet established fisetin as an anti-aging treatment. Researchers are testing fisetin in several populations and measuring outcomes including cellular-senescence markers, vascular function and physical function.

Why human trials matter

The frequently cited 2018 fisetin research demonstrated senotherapeutic activity in experimental models and reported improvements in health and lifespan measures in aged mice.

That provided a reason to investigate fisetin in people. It did not prove that fisetin slows human aging or extends human lifespan.

Clinical trials are needed to determine safety, absorption and metabolism, biological activity, appropriate research protocols and whether changes in biomarkers translate into meaningful improvements in human health.

For the background science, see our guide to what the fisetin and senolytic evidence actually shows.

For the broader picture beyond fisetin, read our guide to what human senolytic clinical trials have found so far.

Vascular function in older adults

A University of Colorado Boulder Phase 1/2 study is investigating fisetin in adults aged 65 and older. The randomized, placebo-controlled trial is designed to examine whether intermittent fisetin treatment improves endothelial function and reduces aortic stiffness.

Researchers are also measuring biological markers associated with cellular senescence, including p16 and p21 in endothelial cells, p16-positive T cells, and circulating factors associated with the senescence-associated secretory phenotype (SASP).

The study is particularly interesting because it attempts to connect a potential senolytic intervention with both molecular measurements and an actual physiological outcome: vascular function.

Low-dose fisetin and healthy aging

A newer randomized, triple-blind, placebo-controlled study is investigating daily low-dose fisetin in generally healthy adults aged 50 and older.

The study is examining chronic inflammation using plasma suPAR as its primary biomarker while also assessing safety, adverse events, additional biomarkers and functional outcomes.

This study takes a different approach from trials using short periods of higher experimental exposure. Comparing different research strategies may eventually help scientists understand how fisetin behaves in humans and which approaches, if any, produce useful biological effects.

Fisetin after breast-cancer treatment

The Phase 2 TROFFi study is testing whether targeting cellular senescence with fisetin can improve physical function in postmenopausal breast-cancer survivors who experienced diminished physical function following chemotherapy.

The primary outcome is change in six-minute walking distance. Researchers are also collecting biological measures related to senescence. This is an example of investigators testing senolytic biology in a specific clinical setting rather than treating “aging” itself as a disease.

Other human studies are testing different clinical settings

Fisetin is also being investigated in other populations, including people with sepsis and people with mild Alzheimer’s disease. These studies are useful because they test whether fisetin’s proposed senotherapeutic effects translate into measurable changes in very different biological and clinical contexts.

That diversity is scientifically valuable. If fisetin affects senescent-cell biology in humans, researchers need to understand whether those effects are consistent across tissues, diseases and dosing strategies rather than assuming one result applies universally.

What do these trials prove today?

They prove that fisetin has moved beyond laboratory speculation and into serious human investigation.

They do not yet prove that fisetin clears senescent cells throughout the human body, reverses aging, prevents age-related disease, or extends human lifespan.

Some studies are still recruiting or active, some are focused on specific patient populations, and many are designed around biomarkers or functional outcomes rather than lifespan itself.

Why trial design matters

Different fisetin studies use different doses, schedules, populations and endpoints. That means one trial cannot automatically answer every question about fisetin.

A short intermittent protocol may test a different biological hypothesis from daily low-dose use. A study in cancer survivors may reveal something different from a study in healthy older adults. Researchers therefore need multiple well-designed trials before broad conclusions are justified.

What questions are human fisetin trials trying to answer?

Human fisetin research is not testing one single claim. Different clinical trials are examining different biological and clinical questions.

Researchers may measure markers of cellular senescence, inflammation, vascular function, physical performance, safety, tolerability or disease-specific outcomes. These endpoints are not interchangeable.

A study showing a change in a biomarker does not automatically demonstrate that fisetin improves health, prevents disease or slows aging. Clinical significance has to be established separately.

What is the Fisetin LOW healthy-aging trial?

One of the newer human studies is the Fisetin Supplementation for Healthy Aging trial, also known as Fisetin LOW.

The study is designed as a triple-blind, randomized, placebo-controlled trial involving approximately 120 relatively healthy middle-aged and older adults.

Researchers are evaluating safety together with measures related to chronic inflammation, cellular senescence and general health. The study includes biomarkers such as SASP-related factors and senescence markers in immune cells.

As of the latest ClinicalTrials.gov record, the study is recruiting and has not posted results. Its estimated completion is in 2026.

This is an important distinction: a registered trial shows that researchers are testing a hypothesis. It does not show that the hypothesis has been confirmed.

Why are researchers measuring senescence biomarkers?

Because there is no validated test that measures a person’s total senescent-cell burden throughout the body, clinical trials often rely on combinations of biomarkers.

Examples include p16, p21, senescence-associated beta-galactosidase and components of the senescence-associated secretory phenotype.

Researchers may also examine whether changes in these biomarkers correspond with changes in physical function, vascular measures or other clinical outcomes.

Learn how scientists measure cellular senescence →

Why does trial status matter?

ClinicalTrials.gov records can describe studies that are recruiting, active, completed or terminated. These statuses tell readers where a study is in the research process, but they do not indicate whether the treatment was successful.

A completed trial may still have no publicly posted results. A recruiting trial has not yet generated final evidence. Even when results are published, the study design, number of participants and endpoints must be considered before drawing conclusions.

For emerging longevity research, distinguishing between a registered trial and a completed trial with peer-reviewed results is especially important.

How should fisetin trial results be interpreted?

Fisetin trials should be interpreted according to the outcomes they were designed to measure.

A study focused on vascular function may not answer questions about cognition, muscle function or lifespan. Likewise, a study showing changes in inflammatory markers may not establish that participants experienced meaningful improvements in health.

The strongest conclusions usually come from randomized, placebo-controlled trials with clearly defined primary outcomes and enough participants to detect clinically meaningful differences.

What are the biggest limitations in current human fisetin research?

Several limitations make it difficult to draw broad conclusions from the current human evidence.

• Many studies are small or still recruiting.
• Different trials use different populations, endpoints and treatment schedules.
• Some studies focus primarily on biomarkers rather than clinical outcomes.
• There is limited long-term safety information for repeated higher-exposure use.
• Results from people with a specific disease may not apply to healthy adults.

These limitations do not make the research unimportant. They simply mean that the evidence is still developing.

What would stronger evidence look like?

Stronger evidence would include larger randomized controlled trials that reproduce findings across different populations and measure outcomes that matter clinically.

Researchers would also need to establish whether changes in senescence biomarkers correspond with improvements in function, disease risk or quality of life.

Longer follow-up would help clarify whether any benefits persist and whether repeated treatment introduces safety concerns.

Does the existence of clinical trials mean fisetin is proven?

No. Clinical trials are part of the process used to determine whether a scientific hypothesis is correct.

The fact that fisetin is being studied in humans makes it scientifically relevant, but it should not be interpreted as proof that fisetin slows aging, clears senescent cells throughout the body or extends human lifespan.

Those claims would require substantially stronger human evidence than currently exists.

What should readers watch for next?

The most informative developments will be completed randomized trials with publicly available results, peer-reviewed publications and replication by independent research groups.

Useful questions to ask when new results appear include:

• Was the study randomized and placebo controlled?
• How many participants were included?
• Were the primary outcomes biomarkers or clinical outcomes?
• Were the findings statistically and clinically meaningful?
• Were adverse events reported clearly?
• Have similar results been reproduced elsewhere?

Zombie Cell Science will update its coverage as stronger human evidence becomes available.

Read how Zombie Cell Science evaluates clinical evidence →

The takeaway

Human fisetin research is expanding, and that is the most important development in the field. Scientists are now testing questions about safety, senescence markers, inflammation, vascular function, physical performance and disease-specific outcomes in people.

The evidence is becoming more informative, but the correct conclusion today is still cautious: fisetin is a promising senotherapeutic candidate under active investigation, not a proven human anti-aging treatment.

For related background, read what senolytics are, why researchers are studying fisetin, and which foods naturally contain fisetin.

Educational information only; not medical advice. Clinical-trial discussion does not constitute a recommendation to use fisetin or any other supplement or treatment.